8-K: Rigel Reports Strong 2025, Positive 2026 Outlook

Rigel Pharmaceuticals announced preliminary strong fourth quarter and full-year 2025 financial results, provided a positive 2026 outlook with anticipated profitability, and shared encouraging clinical updates across its pipeline.

Summary

• Preliminary Q4 2025 total revenue reached $69.8 million, up from $57.6 million in Q4 2024, with net product sales of $65.4 million.
• Full-year 2025 total revenue is expected to be $294.3 million, a significant increase from $179.3 million in 2024, driven by 60% growth in net product sales to $232.0 million.
• Cash, cash equivalents, and short-term investments grew to approximately $154.6 million by December 31, 2025, from $77.3 million at the end of 2024.
• The company projects full-year 2026 total revenue between $275 million and $290 million, including net product sales of $255 million to $265 million, and anticipates positive net income for the year.
• In the Phase 1b study of R289 for lower-risk MDS, 33% (6/18) of evaluable transfusion-dependent patients achieved red blood cell transfusion independence (RBC-TI) at doses of 500 mg QD or higher.
• Enrollment for the dose expansion phase of the R289 Phase 1b study is on track for completion in the second half of 2026, with preliminary data expected by year-end 2026.
• Updated data for olutasidenib (REZLIDHIA) and pralsetinib (GAVRETO) from various studies were presented, showing durable responses and robust activity in respective cancer types.
• The FDA approved a Prior Approval sNDA for GAVRETO, adding a boxed warning for serious infections to its U.S. Prescribing Information.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary financial results for 2025, significant growth in product sales, a substantial increase in cash, and a positive outlook for 2026 with anticipated profitability. Clinical pipeline updates are generally positive, with promising data for R289 and continued development for other products. The only notable negative is a new boxed warning for GAVRETO, which was previously communicated, but the overall financial and clinical progress is very strong.

Positives

• Preliminary Q4 2025 total revenue of $69.8 million significantly increased from $57.6 million in Q4 2024.
• Preliminary Q4 2025 net product sales grew to $65.4 million from $46.5 million in Q4 2024, representing strong commercial execution.
• Full-year 2025 total revenue is expected to be $294.3 million, a substantial increase from $179.3 million in 2024.
• Net product sales for the full year 2025 are projected to be $232.0 million, demonstrating 60% growth compared to 2024.
• Cash, cash equivalents, and short-term investments nearly doubled to $154.6 million as of December 31, 2025, from $77.3 million at the end of 2024.
• Anticipates positive net income for the full year 2026, while funding existing and new clinical development programs.
• R289 in lower-risk MDS Phase 1b study showed 33% (6/18) of evaluable transfusion-dependent patients achieved RBC-TI at doses >=500 mg QD, indicating promising preliminary efficacy.
• Pralsetinib demonstrated robust and durable activity against RET fusion-positive solid tumors, including GI tumors, with an overall response rate (ORR) of 67% (26/39) in the TAPISTRY study.
• Olutasidenib's final 5-year data from the Phase 2 pivotal cohort further support durable responses and a manageable safety profile in R/R mIDH1 AML.

Negatives

• The U.S. FDA approved a Prior Approval supplemental New Drug Application for GAVRETO, adding a boxed warning regarding serious infections, including opportunistic infections, to its U.S. Prescribing Information.

Risks

• Finalization and audit of 2025 fiscal year financial results could lead to changes or adjustments to the preliminary financial results and projections.
• Risks and uncertainties are associated with the commercialization and marketing of TAVALISSE, GAVRETO, and REZLIDHIA.
• Regulatory authorities (FDA, EMA, PMDA) may make adverse decisions regarding TAVALISSE, GAVRETO, REZLIDHIA, or R289.
• Clinical trials may not be predictive of real-world results or results in subsequent clinical trials.
• TAVALISSE, GAVRETO, REZLIDHIA, or R289 may have unintended side effects, adverse reactions, or incidents of misuses.
• The availability of resources to develop or market product candidates is a factor.
• Market competition poses a risk.
• Other risks detailed from time to time in SEC reports, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and subsequent filings.

Future Outlook

Rigel anticipates continued strong commercial performance and clinical advancement in 2026, projecting full-year total revenue between $275 million and $290 million, with net product sales of $255 million to $265 million. The company expects to achieve positive net income for the full year 2026, supporting both existing and new clinical development programs. Key milestones include completing enrollment and selecting a Phase 2 dose for R289 in lower-risk MDS in the second half of 2026, with preliminary data from the dose expansion phase expected by year-end 2026. Rigel also plans to explore opportunities to add new products to its portfolio.

Management Comments

• "2025 was an excellent year for Rigel, marked by strong commercial execution with record net product sales; significant financial progress, including continued profitability and generation of $77 million in cash; and meaningful clinical advancement of R289 in lower-risk MDS, where we shared encouraging Phase 1b data."
• "In 2026, we plan to continue to execute across all areas of the business – driving sustained commercial performance, supporting our expanding clinical programs with a solid financial foundation, delivering preliminary results from the dose expansion phase of our R289 study and continuing to explore opportunities to add new products to our portfolio."

Industry Context

Rigel operates in the competitive biotechnology sector, focusing on hematologic disorders and cancer, areas with significant unmet medical needs. The positive financial performance and pipeline advancements, particularly in MDS, AML, and NSCLC, position Rigel to potentially capture larger market shares in these therapeutic areas. The continued development of R289 for lower-risk MDS addresses a patient population with limited effective treatment options, while updates on GAVRETO and REZLIDHIA reinforce their roles in specific cancer subtypes. The boxed warning for GAVRETO highlights the ongoing regulatory scrutiny and safety considerations common in the pharmaceutical industry. The company's focus on profitability and cash generation is a positive signal in an industry often characterized by high R&D costs.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, significant cash generation, positive 2026 outlook with anticipated profitability, and promising clinical pipeline advancements.
• Patients: Potential benefit from continued development of R289 for lower-risk MDS and ongoing research supporting existing therapies like olutasidenib and pralsetinib.
• Healthcare Providers: Important safety information update for GAVRETO (boxed warning for serious infections) requires awareness and careful patient management.
• Employees: Positive outlook and expanding clinical programs suggest stability and potential growth opportunities.

Next Steps

• Rigel expects to provide complete fourth quarter and full year 2025 financial results in March 2026.
• Raul Rodriguez, Rigel's president and CEO, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
• Rigel plans to complete enrollment in the dose expansion phase of the R289 Phase 1b study and select the recommended Phase 2 dose in the second half of 2026.
• The company anticipates sharing preliminary data from the dose expansion phase of the R289 study by the end of 2026.
• Rigel plans to continue exploring opportunities to add new products to its portfolio.

Key Dates

Recommendation

The filing presents exceptionally strong preliminary financial results for 2025, including record net product sales and a near-doubling of cash. The 2026 outlook projects continued revenue growth and, critically, positive net income for the full year, indicating a transition to sustained profitability. Clinical pipeline advancements, particularly the encouraging Phase 1b data for R289 in lower-risk MDS and robust activity shown by pralsetinib, suggest future growth drivers. While the GAVRETO boxed warning is a negative, it was previously communicated and does not overshadow the overall positive financial and clinical momentum. The company appears to be executing well on its commercial strategy and advancing its pipeline, making it an attractive investment.

Keywords

Rigel Pharmaceuticals, RIGL, biotechnology, hematologic disorders, cancer, SEC filing, financial results, 2026 outlook, TAVALISSE, fostamatinib, GAVRETO, pralsetinib, REZLIDHIA, olutasidenib, R289, MDS, immune thrombocytopenia, ITP, non-small cell lung cancer, NSCLC, acute myeloid leukemia, AML, clinical trials, drug development, FDA approval, oncology